Which people actually benefit?
Subgroup effects hide in average null trials. Better stratification is the next paper, not a slogan.
The field is moving from 'a lactobacillus' to defined mixes with drug-style evidence. Most shelf products will not make that jump.
Personalisation claims run ahead of trials. This atlas stays sceptical on purpose.
Open questions
Can consortia beat single strains?
Defined mixes are in trials. Complexity raises manufacturing risk.
How should labels be policed?
Strain IDs, viable counts at expiry and banned disease claims are the boring essentials.
Do they permanently change the microbiome?
Usually no. Transient detection is the common finding.
What about next-gen engineered strains?
Research exists. This atlas will not discuss construction or release methods.
The frontier is better evidence, not a home-culture kit.
Keep exploring
More in Beneficial allies
Gut microbiome
A diverse intestinal community fed by fibre — not a single ideal species list and not a wellness shop.
Familiarity 88Fermentation
Microbes turning food into kimchi, doenjang, yoghurt and other living crafts — chemistry plus culture.
Familiarity 85Skin microbiome
A site-specific living film — oily, moist and dry neighbourhoods, not a sterile wrapper.
Familiarity 62Soil microbes
The hidden workforce of land — decomposers, mycorrhizae and a mostly uncultured majority.
Familiarity 48Nitrogen cycle
How microbes move nitrogen between air, soil, water and food — plus the industrial shortcut that feeds billions.
Familiarity 40